Research ArticleCancer

Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events

See allHide authors and affiliations

Science Translational Medicine  08 Nov 2017:
Vol. 9, Issue 415, eaan0401
DOI: 10.1126/scitranslmed.aan0401

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Keeping immunotherapy closer to home

Immune checkpoint inhibitors are gaining increasing prominence in the field of cancer because of their remarkable success record in many difficult-to-treat tumor types. Unfortunately, activation of the immune system against tumors does not occur in isolation, and these drugs are also associated with a host of immune side effects, which limit their usefulness. To decrease systemic toxicity, Ishihara et al. conjugated immune checkpoint antibodies to a matrix-binding peptide and showed that peritumoral injection of these conjugated antibodies results in their retention in tumor tissue, effective antitumor response, and systemic antitumor immunity with fewer adverse effects.